RNS Number : 6036E
Haleon PLC
18 May 2026
Haleon plc: Aggregated information - transactions in own shares
18 May 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 8,316,688 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Aquis
Date of purchase:
11 May 2026
Number of Shares purchased:
1,338,672
850,639
989,996
-
Highest price paid per Share (p):
333.1000
333.0000
333.0000
-
Lowest price paid per Share (p):
326.6000
326.6000
326.6000
-
Volume weighted average price paid per Share (p):
328.7510
328.3012
328.5150
-
Date of purchase:
12 May 2026
Number of Shares purchased:
136,968
73,601
88,439
-
Highest price paid per Share (p):
332.0000
330.9000
332.0000
-
Lowest price paid per Share (p):
325.4000
325.4000
325.4000
-
Volume weighted average price paid per Share (p):
327.7318
327.9542
327.6454
-
Date of purchase:
13 May 2026
Number of Shares purchased:
607,723
502,225
490,052
-
Highest price paid per Share (p):
331.7000
331.7000
331.7000
-
Lowest price paid per Share (p):
329.9000
329.9000
329.9000
-
Volume weighted average price paid per Share (p):
330.9437
330.8733
330.9219
-
Date of purchase:
14 May 2026
Number of Shares purchased:
487,742
353,903
407,856
-
Highest price paid per Share (p):
332.8000
332.8000
332.8000
-
Lowest price paid per Share (p):
329.4000
329.4000
329.4000
-
Volume weighted average price paid per Share (p):
331.1191
331.1758
331.1625
-
Date of purchase:
15 May 2026
Number of Shares purchased:
950,986
408,698
629,188
-
Highest price paid per Share (p):
332.3000
332.3000
332.3000
-
Lowest price paid per Share (p):
329.0000
329.0000
329.0000
-
Volume weighted average price paid per Share (p):
330.7060
330.7844
330.7188
-
Following the settlement of the above, the Company's registered share capital is 8,871,945,578 ordinary shares of £0.01 each, of which 12,130,560 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,859,815,018 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/6036E_1-2026-5-15.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
Investors
Media
Jo Russell
+44 7787 392441
ZoëBird
+44 7736 746167
Rakesh Patel
+44 7552 484646
Victoria Durman
+44 7894 505730
Email:investor-relations@haleon.com
Email:corporate.media@haleon.com
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSBLGDURSBDGLU
